Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Junior Politicians Set Up Vaccine Study Group
May 31, 2019
-
BUSINESS Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
-
REGULATORY Alnylam’s RNAi Drug Now in Line for Japan Approval in June
May 29, 2019
-
TRENDS Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
-
BUSINESS NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
-
BUSINESS MSD’s Zerbaxa Launch Being Shelved after Foreign Particles Detected
May 27, 2019
-
BUSINESS Big 3 Generic Makers Eke Out Growth in Japan, but Struggle in US; AG Momentum Continues: Jiho Tally
May 24, 2019
-
BUSINESS AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
-
ACADEMIA Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
-
BUSINESS Japan Pharma Market Shrinks 1.8% in FY2018: IQVIA
May 22, 2019
-
BUSINESS Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
-
BUSINESS Top 4 Wholesalers See Over 1% Operating Margins in FY2018, Thanks Partly to Distribution Improvement Guidelines
May 20, 2019
-
REGULATORY Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
May 17, 2019
-
BUSINESS 21 Japan Drug Makers’ Combined Sales Up 5% in FY2018, but Flagging Japan Biz Continues
May 16, 2019
-
REGULATORY 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
May 15, 2019
-
REGULATORY Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
-
BUSINESS 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
-
BUSINESS Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
-
BUSINESS Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
-
INTERVIEW As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
May 8, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…